Li C et al. |
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29022084
|
Cox K et al. |
Emerging Therapeutic Strategies in Breast Cancer. |
2017 |
South. Med. J. |
pmid:28973703
|
Kolodych S et al. |
Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. |
2017 |
Eur J Med Chem |
pmid:28818506
|
Du ZQ et al. |
Combination of traditional mutation and metabolic engineering to enhance ansamitocin P-3 production in Actinosynnema pretiosum. |
2017 |
Biotechnol. Bioeng. |
pmid:28782796
|
Diaby V et al. |
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. |
2017 |
Breast Cancer Res. Treat. |
pmid:28840424
|
Sabbaghi M et al. |
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:28821558
|
He X et al. |
Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. |
2017 |
Nano Lett. |
pmid:28758755
|
Loebrich S et al. |
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. |
2017 |
AAPS J |
pmid:28534292
|
Meng H et al. |
A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. |
2017 |
Macromol Biosci |
pmid:28464449
|
Singh AP and Shah DK |
Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). |
2017 |
AAPS J |
pmid:28374319
|